Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Saxenda (liraglutide) for the Treatment of Obesity

Drug (Brand / Generic)

Saxenda / liraglutide

Company / Licensee

Novo Nordisk

Product Description

Glucagon-like peptide-1 (GLP-1) receptor agonist

Current Indication

Obesity and overweight

Market Sector

Anti-obesity drugs

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top